CLINUVEL PHARMACEUTICALS LTD

Home
Australia
Melbourne, VIC
CLINUVEL PHARMACEUTICALS LTD

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CLINUVEL PHARMACEUTICALS LTD, Medical and health, 535 Bourke Street, Melbourne.

CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations.

28/05/2026

We’re proud to support the Multidisciplinary Porphyria Symposium taking place today in the Netherlands.

The event brings clinicians and laboratory specialists together to deepen understanding of porphyria through real-world cases and collaboration.

Advancing porphyria care requires this kind of cross-disciplinary exchange. By sharing insights on diagnosis and treatment, we can help drive earlier detection, better patient outcomes, and continued innovation for those living with these rare conditions.

26/05/2026

At , Shahnawaz Towheed shared his powerful journey—how losing his pigment through vitiligo became the driving force behind his path into a future career as a dermatologist.

Along the way, he founded Vitiligo Voices Canada, creating a platform to uplift community voices, challenge stigma and offer meaningful support.

Discover more about Shahnawaz’s story in the interview on our Vitiligo Hub: https://www.clinuvel.com/2026/02/interview-shahnawaz-towheed/

18/05/2026

Today is .

This annual initiative brings together the international porphyria community to raise awareness of this group of rare disorders, with people being encouraged to wear purple to mark the occasion.
Erythropoietic protoporphyria ( ) is estimated to impact 5,000–10,000 people globally.

CLINUVEL is dedicated to supporting patients globally and improving outcomes for those living with EPP and other forms of porphyria.

08/05/2026

Imagine the feeling of never being able to enjoy a day in the sun with your loved ones, having to isolate yourself indoors and cover up with protective clothing to prevent debilitating phototoxic reactions.

This is a common experience for people living with the rare metabolic disorder erythropoietic protoporphyria (EPP) like George Hodder.

At , we had the privilege of hearing George share his inspiring journey with EPP.

Thank you, George for inspiring us all and empowering the EPP community.

06/05/2026

One of the highlights of was connecting with the global dermatology community.

Hear from our team sharing their experiences of interactions with guests at the Pavilion of Photomedicine and the overall energy of AAD 2026.

29/04/2026

Tonja Johnson joined CLINUVEL at the Pavilion of Photomedicine during for an inspiring panel discussion on vitiligo and the importance of psychodermatology.

Head to the CLINUVEL Vitiligo Hub to learn more about Tonja’s story and the founding of the Beautifully Unblemished Vitiligo Support Group: https://brnw.ch/21x21Wl

27/04/2026

CLINUVEL announced that the U.S. Food and Drug Administration (FDA) has reviewed the long-term safety profile of SCENESSE® (afamelanotide) and removed a requirement for a post-authorization phase I study on cardiac repolarization (a “QT study”).

“There is an active engagement between the FDA and marketing authorization holders for the life span of a product where patient safety is paramount,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer.

“Having reliably reported data on SCENESSE® since 2019, we are now seeing the agency relax its approach to postmarketing demands, reflecting the safety profile we see in the clinic.”

Learn more in the announcement here:https://www.clinuvel.com/wp-content/uploads/2026/04/20260427-fda-relaxes-scenesse-postmarketing-requirement.pdf

24/04/2026

The European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s drug SCENESSE® (afamelanotide) as a systemic vitiligo treatment.

The EMA proposed to evaluate the efficacy of SCENESSE® in vitiligo based on a regulatory approach of “totality of evidence”, with T-VASI50 the primary endpoint while patient reported outcomes and clinical data from the other vitiligo studies with SCENESSE® will be evaluated for final analyses of efficacy and safety.

Learn more in the announcement here: https://brnw.ch/21x1T9L

23/04/2026

At , Shahnawaz Towheed shared his unique story of how losing his pigment motivated him to pursue a career in the medical field.

Alongside his studies, Shahnawaz established Vitiligo Voices Canada, helping to amplify community voices, reduce stigma, and provide support.

Head to the CLINUVEL Vitiligo Hub to learn more about Shahnawaz’s journey: https://brnw.ch/21x1R5E

Address

535 Bourke Street
Melbourne, VIC
3000

Telephone

+61396604900

Website

https://www.clinuvel.com/

Alerts

Be the first to know and let us send you an email when CLINUVEL PHARMACEUTICALS LTD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Featured

Heidelberg Dermatology
5 Burgundy Street, Heidelberg
Dr Namal Plastic Surgeon
Day Surgery Centre, Blanton Drive